Levobupivacaine

Synonyms: (S)-(-)-Bupivacaine
Levobupivacaine ((S)-(-)-Bupivacaine) 是一种长效酰胺类局部活性剂,可通过可逆性阻断神经元钠通道 (sodium channel) 发挥麻醉镇痛作用,从而抑制或缓解疼痛,同时可抑制心血管等组织的传递和传导冲动并具有一定的心脏和中枢神经毒性,在体内由细胞色素P450 (CYP450) 代谢,也可通过 miR-489-3p/SLC7A11 信号通路诱导胃癌铁死亡 (ferroptosis)。
产品编号: MS-A97912 纯度: 99.66% CAS No.: 27262-47-1 分子式: C18H28N2O 分子量: 288.43
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

Levobupivacaine ((S)-(-)-Bupivacaine) 是一种长效酰胺类局部活性剂,可通过可逆性阻断神经元钠通道 (sodium channel) 发挥麻醉镇痛作用,从而抑制或缓解疼痛,同时可抑制心血管等组织的传递和传导冲动并具有一定的心脏和中枢神经毒性,在体内由细胞色素P450 (CYP450) 代谢,也可通过 miR-489-3p/SLC7A11 信号通路诱导胃癌铁死亡 (ferroptosis)。

生物实验数据

生物活性 Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide-type local anesthetic that exerts anesthetic and analgesic effects by reversibly blocking neuronal sodium channels, thereby inhibiting or relieving pain, and can also inhibit impulse transmission and conduction in cardiovascular and other tissues with certain cardiac and central nervous system toxicity, is metabolized in vivo by cytochrome P450 (CYP450), and can also induce ferroptosis in gastric cancer through the miR-489-3p/SLC7A11 signaling pathway.
IC50 & Target

Sodium channels, Ferroptosis

体外研究
(In Vitro)

Levobupivacaine (0-4 mM; 24 h) does not affect the viability of GES-1 cells but inhibits the viability of HGC27 and SGC7901 cells.
Levobupivacaine (2 mM; 24, 48 or 72 h) enhances Erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities; induces the levels of Fe2+, iron, and lipid ROS.
Levobupivacaine (2 mM; 24 h) enhances the expression of miR-489-3p in HGC27 and SGC7901 cells, increases the levels of Fe2+ and iron.

Cell Viability Assay

Cell Line: GES-1, HGC27 and SGC790
Concentration: 0, 0.5, 1, 2 and 4 mM
Incubation Time: 24 h
Result: Did not affect the viability of normal gastric epithelial GES-1 cell lines but inhibited the viability of HGC27 and SGC7901 cells in a dose-dependent manner.

Cell Viability Assay

Cell Line: HGC27 and SGC7901 (incubated with 5 μM erastin)
Concentration: 2 mM
Incubation Time: 24, 48 or 72 h
Result: Enhanced erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities; induced the levels of Fe2+, iron, and lipid ROS.

RT-PCR

Cell Line: HGC27 and SGC7901 (incubated with 5 μM erastin)
Concentration: 2 mM
Incubation Time: 24 h
Result: Enhanced the expression of miR-489-3p in HGC27 and SGC7901 cells, increased the levels of Fe2+ and iron.
体内研究
(In Vivo)

Levobupivacaine (40 μmol/kg; IP; once daily for 25 days) significantly inhibits SGC7901 cell growth, and enhances the lipid ROS accumulation.
Levobupivacaine (5 or 36 mg/kg; IP; single dosage) increases the latency to partial seizures and prevents the occurrence of generalized seizures at low dosage; reduces the latency to N-methyl-d-aspartate (NMDA)-induced seizures and increased seizure severity at high dosage.

Animal Model: CD1 mice (30-35 g; induced epileptic seizures by injecting with NMDA)
Dosage: 5 or 36 mg/kg
Administration: IP; single dosage
Result: Increased the latency to partial seizures and prevented the occurrence of generalized seizures at 5 mg/kg; reduced the latency to NMDA-induced seizures and increased seizure severity at 36 mg/kg.
Animal Model: SCID nude mice (6-8 weeks; subcutaneously injected with 5×106 SGC7901 cells)
Dosage: 40 μmol/kg
Administration: IP; once daily for 25 days
Result: Significantly inhibited SGC7901 cell growth, and enhanced the lipid ROS accumulation.
性状 固体
颜色 White to off-white

化学信息

分子量 288.43
分子式 C18H28N2O
CAS No. 27262-47-1
别名 (S)-(-)-Bupivacaine

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 29.17 mg/mL (101.13 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.4670 mL17.3352 mL34.6705 mL86.6761 mL
5 mM0.6934 mL3.4670 mL6.9341 mL17.3352 mL
10 mM0.3467 mL1.7335 mL3.4670 mL8.6676 mL
15 mM0.2311 mL1.1557 mL2.3114 mL5.7784 mL
20 mM0.1734 mL0.8668 mL1.7335 mL4.3338 mL
25 mM0.1387 mL0.6934 mL1.3868 mL3.4670 mL
30 mM0.1156 mL0.5778 mL1.1557 mL2.8892 mL
40 mM0.0867 mL0.4334 mL0.8668 mL2.1669 mL
50 mM0.0693 mL0.3467 mL0.6934 mL1.7335 mL
60 mM0.0578 mL0.2889 mL0.5778 mL1.4446 mL
80 mM0.0433 mL0.2167 mL0.4334 mL1.0835 mL
100 mM0.0347 mL0.1734 mL0.3467 mL0.8668 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础